FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?

FDA advisers narrowly voted to add six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to a compounding list, allowing specialty pharmacies to legally prepare them with a doctor's prescription, though the recommendation is non-binding and requires FDA sign-off. The decision reflects political pressure from HHS Secretary Kennedy and a deep divide between industry-backed advisers and FDA scientists, who unanimously opposed the additions citing lack of clinical data and quality control risks.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.